Macquarie Group Ltd. increased its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 15.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,069,323 shares of the company’s stock after acquiring an additional 282,559 shares during the period. Macquarie Group Ltd. owned about 1.65% of Catalent worth $82,607,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Acrospire Investment Management LLC boosted its position in Catalent by 72.2% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares during the last quarter. Quantbot Technologies LP boosted its position in Catalent by 110.7% in the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after buying an additional 1,804 shares during the last quarter. Fortaleza Asset Management Inc. bought a new position in Catalent in the 3rd quarter valued at $164,000. PNC Financial Services Group Inc. boosted its position in Catalent by 66.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 6,070 shares of the company’s stock valued at $173,000 after buying an additional 2,425 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Catalent by 12.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after buying an additional 559 shares during the last quarter. Institutional investors and hedge funds own 99.49% of the company’s stock.
A number of brokerages have commented on CTLT. Needham & Company LLC began coverage on Catalent in a research report on Tuesday, September 12th. They issued a “hold” rating and a $42.00 price objective on the stock. BidaskClub lowered Catalent from a “buy” rating to a “hold” rating in a research report on Friday, September 15th. Bank of America reiterated a “buy” rating and issued a $40.00 price objective (up from $38.00) on shares of Catalent in a research report on Tuesday, August 29th. Piper Jaffray Companies reissued a “buy” rating and issued a $45.00 price target on shares of Catalent in a research note on Tuesday, August 29th. Finally, Zacks Investment Research downgraded Catalent from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $44.25.
In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The shares were acquired at an average price of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.70% of the company’s stock.
Catalent, Inc. (CTLT) traded down $0.92 during mid-day trading on Monday, hitting $37.88. The stock had a trading volume of 563,459 shares, compared to its average volume of 858,529. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91. The firm has a market cap of $5,030.00, a P/E ratio of 27.13, a P/E/G ratio of 2.49 and a beta of 1.41. Catalent, Inc. has a one year low of $23.03 and a one year high of $43.39.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million for the quarter, compared to the consensus estimate of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.16 EPS. analysts predict that Catalent, Inc. will post 1.46 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Macquarie Group Ltd. Purchases 282,559 Shares of Catalent, Inc. (CTLT)” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/04/catalent-inc-ctlt-stake-lifted-by-macquarie-group-ltd.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.